Yechiel Yaniv, Chicheportiche Alexandre, Keidar Zohar, Ben-Haim Simona
Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel.
Department of Biophysics and Nuclear Medicine, Hadassah Medical Organization, Jerusalem, Israel.
PET Clin. 2024 Jul;19(3):389-399. doi: 10.1016/j.cpet.2024.03.011. Epub 2024 Apr 27.
Prostate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant metastases have 5 year survival rates of approximately 30%. Initial diagnosis and assessment are based on PSA levels, Gleason score (derived from prostate biopsy), and advanced imaging modalities, including prostate MR imaging and PSMA-PET/computed tomography in patients with high-risk features.
前列腺癌是全球男性中最常见的恶性肿瘤，在美国估计每年有174,650例新发病例，是仅次于肺癌的第二大致癌死亡原因，每年有31,620人死亡。虽然没有发生转移扩散的前列腺癌患者的5年生存率接近100%，但有远处转移的患者5年生存率约为30%。初始诊断和评估基于前列腺特异性抗原（PSA）水平、 Gleason评分（源自前列腺活检）以及先进的成像方式，包括前列腺磁共振成像和针对具有高危特征患者的PSMA-PET/计算机断层扫描。
